Jaguar Health (JAGX) Depreciation & Amortization (CF) (2016 - 2026)
Jaguar Health (JAGX) reported Depreciation & Amortization (CF) of $473000.0 for Q1 2026, down 1.25% year-over-year from $479000.0 in Q1 2025, and down 0.84% quarter-over-quarter from $477000.0 in Q4 2025.
Jaguar Health (JAGX) Depreciation & Amortization (CF) (2016 - 2026) Analysis & Trends
Jaguar Health (JAGX) has 11 years of Depreciation & Amortization (CF) data on file, last reported at $473000.0 in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $473000.0, down 1.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 million (up 1.54% YoY), and the FY2025 annual result was $1.9 million, up 0.68% from the prior year.
- Depreciation & Amortization (CF) eased to $473000.0 in Q1 2026 per JAGX's latest filing, from $477000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $558000.0 in Q2 2022 and troughed at $426000.0 in Q1 2022.
- A 5-year average of $487058.8 and a median of $479000.0 in 2025 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) gained 29.77% in 2022, then declined 11.13% in 2024.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $499000.0 in 2022, then advanced by 0.6% to $502000.0 in 2023, then retreated by 4.78% to $478000.0 in 2024, then declined by 0.21% to $477000.0 in 2025, then dropped by 0.84% to $473000.0 in 2026.
- Business Quant data shows JAGX's Depreciation & Amortization (CF) at $473000.0 in Q1 2026, $477000.0 in Q4 2025, and $479000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 1,395.22 |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 429,663.65 |
| 10 | Jaguar Health | 1.44 Mn | -10.19 Mn | 19.11 Mn | 473,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 473,000.00 |
| Mar 31, 2026 | 473,000.00 |
| Dec 31, 2025 | 477,000.00 |
| Dec 31, 2025 | 477,000.00 |
| Sep 30, 2025 | 479,000.00 |
| Sep 30, 2025 | 479,000.00 |
| Jun 30, 2025 | 478,000.00 |
| Jun 30, 2025 | 478,000.00 |
| Mar 31, 2025 | 479,000.00 |
| Mar 31, 2025 | 479,000.00 |
| Dec 31, 2024 | 478,000.00 |
| Dec 31, 2024 | 478,000.00 |
| Sep 30, 2024 | 474,000.00 |
| Sep 30, 2024 | 474,000.00 |
| Jun 30, 2024 | 447,000.00 |
| Jun 30, 2024 | 447,000.00 |
| Mar 31, 2024 | 501,000.00 |
| Mar 31, 2024 | 501,000.00 |
| Dec 31, 2023 | 502,000.00 |
| Dec 31, 2023 | 502,000.00 |